What does Google Patents say about EP3969445B1 (asciminib)?
EP3969445B1 is a European patent publication that Google Patents lists under the title that is associated with asciminib-related technology. To verify the exact process claims and what the patent covers, the most reliable step is to open the record on Google Patents and review:
- the “Claims” section (to see the actual process steps),
- the “Description” (for definitions and embodiments),
- and the “Status” / “Legal events” (to see current procedural posture, if shown).
Because the exact wording of the Google Patents record depends on the entry variant you opened (EP publication vs. family member, and B1 vs. A1), you’ll get the correct process details directly from the claims text on the specific Google Patents page for EP3969445B1.
How can I find the exact asciminib “process” language inside EP3969445B1?
On Google Patents for EP3969445B1, use the page’s in-record search or scroll to:
- “Claims” and look for method/process claim terms such as “A method for…”, “process for…”, “preparing…”, “reacting…”, “reactor…”, “purifying…”, “isolating…”, or “crystallizing…”
- any dependent claims that specify particular conditions (solvent, temperature, time), intermediates, or purification steps.
- the “Description” passages that define intermediates and give examples that match the claimed steps.
If you paste the claim(s) you see on the EP3969445B1 Google Patents page (or share the Google Patents link), I can help translate the process into plain language and summarize what is actually claimed.
Is EP3969445B1 likely a synthesis/process patent or a formulation/polymorph patent?
Google Patents typically makes this clear from the claim headers and claim wording. Process patents usually claim methods of:
- making asciminib or key intermediates,
- using specific synthetic routes or purification/crystallization steps.
Formulation/polymorph patents usually claim:
- specific solid forms (polymorphs, salts),
- dosage forms (tablets/capsules),
- specific compositions and their parameters.
The quickest way to tell for EP3969445B1 is to look at whether the independent claim is written as a “method of preparing” asciminib (process) versus a “pharmaceutical composition comprising” (formulation) or “solid form of” (polymorph).
What does “B1” mean on Google Patents for EP3969445B1?
On EP records, “B1” generally indicates the granted patent text (as opposed to an earlier application publication such as “A1”). That matters because:
- the granted claims (B1) are the ones with enforceable scope in Europe (subject to national validation and any amendments).
- the claims may be narrower than the originally published application.
To see how the scope changed, compare the “A1” family member claims (if shown in the same family) with the granted “B1” claims.
Where can I cross-check this in patent-profiling sources?
If you’re trying to map patents to asciminib product families (and see summaries of exclusivity/patent landscape), DrugPatentWatch.com is often used for that purpose, and it may list relevant patents and links to records. You can search there for asciminib and then drill down to the patent family that includes EP3969445B1.
(If you want, tell me which asciminib product/brand context you mean, and I can suggest the most likely family/landscape entry to check on DrugPatentWatch.com.)
Quick next step (so I can give a precise “process” answer)
Send either:
1) the direct Google Patents URL for EP3969445B1, or
2) the text of independent claim 1 (and any dependent process claims you care about).
Then I can summarize exactly what the claimed asciminib process does, what steps it covers, and how that differs from nearby family members or alternative routes.
Sources
- [1] https://patents.google.com/